Mechanism of action of HMG-CoA reductase inhibitors: Medical and chemical aspects of statins;Wirkmechanismus von HMG-CoA-reduktase-inhibitoren: Medizinisch-chemische aspekte von statinen

Pharmazie in Unserer Zeit

Volumn 32, Issue 6, 2003, Pages 464-470

  Stark, Holger ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4 DIMETHOXYPHENYL) 3 (3 ETHYLVALERYL) 4 HYDROXY 6,7,8 TRIMETHOXY 2 NAPHTHOIC ACID METHYL ESTER; 2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ATORVASTATIN; AVASIMIBE; CERIVASTATIN; CHOLESTEROL; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPREVIL; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ARTICLE; CHOLESTEROL SYNTHESIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MECHANISM; IC 50;

EID: 0242665734     PISSN: 00483664     EISSN: None     Source Type: Journal    
DOI: 10.1002/pauz.200300045     Document Type: Article

References (18)

1. Manns, D.: HMG-CoA-Reduktase Hemmer im Überblick. Pharm. Unserer Zeit (1999) 28, 147-152.
2. th edition (2002). D. E. Vance, J. E. Vance (Hrsg,), Elsevier Science B.V., Amsterdam, pp. 409-431.
3. Roth, B.D.: The discovery and development of atorvastatin, a potent novel hypolipidemic agent. Prog. Med. Chem. (2002) 40, 1-22.
4. Manzoni, M., Rollin J. M.: Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl. Microbiol. Biotechnol, (2002) 58, 555-564.
5. th edition (2002). D. A. Williams, T. L. Lemke. (Hrsg.) Lippincott Williams & Wilkins. Philadelphia, USA., pp. 580-600.
6. Istvan, E.S., Deisenhofer, J.: Structural mechanism for statin inhibition of HMG-CoA reductase, Science (2001) 292, 1160-1164.
7. Duriez, R: Current practice in the treatment of hyperlipidaemias. Exp. Opin. Pharmacother. (2001) 2, 1777-1794,
8. Sowers, J.R.: Effects of statins on the vasculature: implications for aggressive lipid management in the cardiovascular metabolic syndrom. Am. J. Cardiol. (2003) 91, 14B-22B.
9. st century: end of the simple story. Expert. Opin. Investig. Drugs (2001) 10, 1755-1766.
10. Veillard, N.R., Mach, F.: Statins: the new aspirins ? Cell. Mol. Life Sci. (2002) 59, 1771-1786.
11. Igel, M., Sudhop, T., von Bergemann, K.: Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin, J. Clin. Pharmacol. (2002) 42, 835-845.
12. Igel, M., Sudhop, T., von Bergmann, K.: Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur. J. Clin. Pharmacol. (2001) 57, 357-364.
13. Bogman, K., Peyer, A.K., Török, M., Küsters, E., Drewe, J.: HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br. J. Pharmacol. (2001) 132, 1183-1192.
14. Bolego, C., Poli, A., Cignarella, A., Catapano, A.L., Paoletti, R.: Novel statins: pharmacological and clinical results. Cardiovasc. Drugs Ther. (2002) 16, 251-257.
15. Yan, L., Lan, F., Wang, Z.G., Li, Y.P.: Statins and myotoxicity. Trends Pharmcol. Sci. (2003) 24, 113-114.
16. Istvan, E.S.: Bacterial and mammalian HMG-CoA reductases: related enzymes with distinct architectures. Curr. Opin. Struct. Biol. (2001) 11, 746-751.
17. Thompson, G.R., Naoumova, R.R: Novel lipid-regulating drugs, Exp. Opin. Invest. Drugs (2000) 9, 2619-2628.
18. Brown, W.V.: Novel approaches to lipid lowering: what is on the horizon? Am. J. Cardiol. (2001) 87 (Suppl.), 23B-27B.